Skip to main content

Advertisement

Log in

Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?

Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

The present study aimed to assess the tolerance and efficacy of rituximab (RTX), a chimeric IgG1 monoclonal antibody directed against the CD20 receptor present in B lymphocytes, in patients with autoimmune rheumatic diseases (AIRD). For this purpose, patients treated with RTX and their respective clinical charts were comprehensively examined. Indications for treatment were a refractory character of the disease, inefficacy or intolerance of other immunosuppressors. Activity indexes (SLEDAI, DAS28, and specific clinical manifestations) were used to evaluate efficacy. Serious side effects were also recorded. Seventy-four patients were included. Forty-three patients had systemic lupus erythematosus (SLE), 21 had rheumatoid arthritis (RA), 8 had Sjögren’s syndrome (SS), and 2 had Takayasu’s arteritis (TA). RTX was well-tolerated in 66 (89%) patients. In 8 patients (SLE = 3, SS = 3, RA = 2), serious side effects lead to discontinuation. The mean follow-up period was 12 ± 7.8 (2–35) months. The efficacy of RTX was registered in 58/66 (87%) patients, of whom 36 (83%) had SLE, 18/21 (85%) had RA, 3/8 (37%) had SS, and 1 had TA. The mean time of efficacy was 6.3 ± 5.1 weeks. A significant steroid-sparing effect was noticed in half of the patients. These results add further evidence for the use of RTX in AIRD. Based on its risk–benefit ratio, RTX might be used as the first-choice treatment for patients with severe AIRD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Youinou P et al (2006) B lymphocytes on the front line of autoimmunity. Autoimmun Rev 5:215–221

    Article  PubMed  Google Scholar 

  2. Reff ME et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445

    PubMed  CAS  Google Scholar 

  3. Shan D, Ledbetter JA, Press OW (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673–683

    Article  PubMed  CAS  Google Scholar 

  4. Einfeld DA et al (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7:711–717

    PubMed  CAS  Google Scholar 

  5. Valentine MA et al (1989) Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 264:11282–11287

    PubMed  CAS  Google Scholar 

  6. Anderson KC et al (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63:1424–1433

    PubMed  CAS  Google Scholar 

  7. Tedder TF et al (1985) The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135:973–979

    PubMed  CAS  Google Scholar 

  8. Tedder TF et al (1990) The CD20 surface molecule of B lymphocytes functions as a calcium channel. J Cell Biochem 14D:195

    Google Scholar 

  9. Press OW et al (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584–591

    PubMed  CAS  Google Scholar 

  10. Cohen SB et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793–2806

    Article  PubMed  CAS  Google Scholar 

  11. Edwards JC et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581

    Article  PubMed  CAS  Google Scholar 

  12. Emery P et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390–1400

    Article  PubMed  CAS  Google Scholar 

  13. Gottenberg JE et al (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:913–920

    Article  PubMed  CAS  Google Scholar 

  14. Higashida J et al (2005) Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol 32:2109–2115

    PubMed  CAS  Google Scholar 

  15. Moore J et al (2004) A phase II study of rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant 34:241–247

    Article  PubMed  CAS  Google Scholar 

  16. Ng CM et al (2005) Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45:792–801

    Article  PubMed  CAS  Google Scholar 

  17. Anolik JH et al (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50:3580–3590

    Article  PubMed  CAS  Google Scholar 

  18. Leandro MJ et al (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46:2673–2677

    Article  PubMed  Google Scholar 

  19. Looney RJ et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580–2589

    Article  PubMed  CAS  Google Scholar 

  20. Smith KG et al (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54:2970–2982

    Article  PubMed  CAS  Google Scholar 

  21. Vigna-Perez M et al (2006) Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8:R83

    Article  PubMed  Google Scholar 

  22. Willems M et al (2006) Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148:623–627

    Article  PubMed  CAS  Google Scholar 

  23. Pijpe J et al (2005) Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum 52:2740–2750

    Article  PubMed  CAS  Google Scholar 

  24. Somer BG et al (2003) Improvement in Sjogren’s syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 49:394–398

    Article  PubMed  Google Scholar 

  25. Voulgarelis M et al (2004) Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren’s syndrome-associated B-cell aggressive non-Hodgkin’s lymphomas. Rheumatology (Oxford) 43:1050–1053

    Article  CAS  Google Scholar 

  26. Tobon GJ, Galarza C, Anaya JM (2005) Rituximab en enfermedades autoinmunes. In: Anaya JM et al (eds) Autoinmunidad y Enfermedad Autoinmune. Corporación para Investigaciones Biológicas, Medellin, pp 441–452

    Google Scholar 

  27. Arnett FC et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  PubMed  CAS  Google Scholar 

  28. Tan EM et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  PubMed  CAS  Google Scholar 

  29. Vitali C et al (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558

    Article  PubMed  CAS  Google Scholar 

  30. Arend WP et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129–1134

    Article  PubMed  CAS  Google Scholar 

  31. Anonymous (1994) Reduced joint counts in rheumatoid arthritis clinical trials. American College of Rheumatology Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 37:463–464

    Article  Google Scholar 

  32. Bombardier C et al (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640

    Article  PubMed  CAS  Google Scholar 

  33. Pichler WJ (2006) Adverse side-effects to biological agents. Allergy 61:912–920

    Article  PubMed  CAS  Google Scholar 

  34. Leandro MJ et al (2003) Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum 48:S378

    Article  Google Scholar 

  35. Cambridge G et al (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48:2146–2154

    Article  PubMed  Google Scholar 

  36. Cartron G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754–758

    Article  PubMed  CAS  Google Scholar 

  37. Dall’Ozzo S et al (2004) Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration–effect relationship. Cancer Res 64:4664–4669

    Article  PubMed  CAS  Google Scholar 

  38. Anolik JH et al (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455–459

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Juan-Manuel Anaya.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galarza, C., Valencia, D., Tobón, G.J. et al. Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?. Clinic Rev Allerg Immunol 34, 124–128 (2008). https://doi.org/10.1007/s12016-007-8028-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-007-8028-z

Keywords

Navigation